NGS Solutions for Diagnosing Infectious Diseases | Illumina Webinar

July 25, 2017

Helene Peyro-Saint-Paul, MD, Chief Medical Officer of PathoQuest provides an overview of the development, validation and clinical evaluation of the iDTECT™ Blood Test. This test uses a Next-generaton sequencing (NGS) shotgun metagenomics approach and is CE-IVD marked to detect pathogens in blood samples, especially in immunocompromised patients. View related videos Next-Generation Sequencing Technology Drives Discoveries in Disease Pathology https://www.youtube.com/watch?v=vv2XR4OpM2M View related information https://www.illumina.com/areas-of-interest/microbiology/microbial-genomics-resources/webinars.html Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc For In Vitro Diagnostic Use.

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.